{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:23:08Z","timestamp":1790799788181,"version":"4.1.0"},"reference-count":103,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An. Bras. Dermatol."],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1590\/abd1806-4841.20176183","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T16:42:00Z","timestamp":1495471320000},"page":"156-166","source":"Crossref","is-referenced-by-count":39,"title":["Melanoma: tumor microenvironment and new treatments"],"prefix":"10.1590","volume":"92","author":[{"given":"Mara Huffenbaecher","family":"Giavina-Bianchi","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Francisco","family":"Giavina-Bianchi Junior","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyro","family":"Festa Neto","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/jid.2008.423","article-title":"Increasing burden of melanoma in the United States","volume":"129","author":"Linos E","year":"2009","journal-title":"J Invest Dermatol"},{"key":"ref2","first-page":"219","article-title":"Cutaneous melanoma","volume":"19-20","author":"Armstrong BK","year":"1994","journal-title":"Cancer Surv"},{"key":"ref3","series-title":"C\u00e2ncer. Pele Melanoma"},{"key":"ref4","series-title":"SEER Stat Facts Sheets: Melanoma of the Skin"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00262-008-0576-4","article-title":"Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy","volume":"58","author":"Baxevanis CN","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2051-1426-2-14","article-title":"Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer","volume":"2","author":"Raval RR","year":"2014","journal-title":"J Immunother Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1084\/jem.188.9.1641","article-title":"Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes","volume":"188","author":"Romero P","year":"1998","journal-title":"J Exp Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00262-005-0018-5","article-title":"Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients","volume":"55","author":"Haanen JB","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"8378","DOI":"10.1158\/0008-5472.CAN-10-2028","article-title":"Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma","volume":"70","author":"Anichini A","year":"2010","journal-title":"Cancer Res"},{"issue":"21","key":"ref10","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","article-title":"Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma","volume":"30","author":"Anichini A","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5","article-title":"Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma","volume":"77","author":"Clemente CG","year":"1996","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/ijc.23543","article-title":"Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression","volume":"123","author":"van Houdt IS","year":"2008","journal-title":"Int J Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1309\/WBF7-N8KH-71KT-RVQ9","article-title":"Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model","volume":"118","author":"Tuthill RJ","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"ref14","first-page":"43","article-title":"Tumor infiltrating lymphocytes in lymph node melanoma met\u00e1stases: a histopathologic prognostic indicator and an expression of local immune response","volume":"74","author":"Mihm Jr MC","year":"1996","journal-title":"Lab Invest"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00262-007-0353-9","article-title":"Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma","volume":"57","author":"Hillen F","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ejca.2009.05.034","article-title":"Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database","volume":"45","author":"Mandal\u00e0 M","year":"2009","journal-title":"Eur J Cancer"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"20429","DOI":"10.1073\/pnas.0905139106","article-title":"Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival","volume":"106","author":"Bogunovic D","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/000313481107700219","article-title":"Prognostic significance of tumor infiltrating lymphocytes in melanoma","volume":"77","author":"Burton AL","year":"2011","journal-title":"Am Surg"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/bjc.2011.189","article-title":"The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis","volume":"105","author":"Gooden MJ","year":"2011","journal-title":"Br J Cancer"},{"key":"ref20","series-title":"Goverment U. C\u00e2ncer treatment"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1038\/jid.2008.226","article-title":"Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside","volume":"128","author":"Hocker TL","year":"2008","journal-title":"J Invest Dermatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman PB","year":"2011","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild A","year":"2012","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty KT","year":"2012","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1203421","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"367","author":"Flaherty KT","year":"2012","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0092-8674(05)80055-8","article-title":"Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7\/BB1 in interleukin-2 production and immunotherapy","volume":"71","author":"Schwartz RH","year":"1992","journal-title":"Cell"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.immunol.14.1.233","article-title":"CD28\/B7 system of T cell costimulation","volume":"14","author":"Lenschow DJ","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd CE","year":"2009","journal-title":"Immunol Rev"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1126\/science.7694363","article-title":"Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation","volume":"262","author":"Freeman GJ","year":"1993","journal-title":"Science"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/366076a0","article-title":"B70 antigen is a second ligand for CTLA-4 and CD28","volume":"366","author":"Azuma M","year":"1993","journal-title":"Nature"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","article-title":"CTLA-4 is a second receptor for the B cell activation antigen B7","volume":"174","author":"Linsley PS","year":"1991","journal-title":"J Exp Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1073\/pnas.87.13.5031","article-title":"T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7\/BB-1","volume":"87","author":"Linsley PS","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi FS","year":"2010","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas A","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok JD","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll DM","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies","volume":"206","author":"Peggs KS","year":"2009","journal-title":"J Exp Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida Y","year":"1992","journal-title":"EMBO J"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir ME","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou W","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian SL","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm0902-1039c","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong H","year":"2002","journal-title":"Nat Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1158\/1078-0432.CCR-04-0428","article-title":"B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression","volume":"10","author":"Konishi J","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown JA","year":"2003","journal-title":"J Immunol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube JM","year":"2012","journal-title":"Sci Transl Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald A","year":"2003","journal-title":"J Exp Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1634\/theoncologist.2012-0123","article-title":"U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma","volume":"17","author":"Herndon TM","year":"2012","journal-title":"Oncologist"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1073\/pnas.94.5.1914","article-title":"A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening","volume":"94","author":"Chen YT","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref49","first-page":"4766","article-title":"The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40","volume":"56","author":"T\u00fcreci O","year":"1996","journal-title":"Cancer Res"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson AJ","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(03)00982-3","article-title":"Cancer\/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies","volume":"4","author":"Juretic A","year":"2003","journal-title":"Lancet Oncol"},{"key":"ref52","series-title":"Cancer immunity. CT database"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ijc.2910630622","article-title":"Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3","volume":"63","author":"Marchand M","year":"1995","journal-title":"Int J Cancer"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1084\/jem.190.11.1669","article-title":"Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma","volume":"190","author":"Thurner B","year":"1999","journal-title":"J Exp Med"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ijc.11045","article-title":"Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178","volume":"105","author":"Bettinotti MP","year":"2003","journal-title":"Int J Cancer"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1084\/jem.187.2.265","article-title":"Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes","volume":"187","author":"J\u00e4ger E","year":"1998","journal-title":"J Exp Med"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(06)95001-5","article-title":"NY-ESO-1: review of an immunogenic tumor antigen","volume":"95","author":"Gnjatic S","year":"2006","journal-title":"Adv Cancer Res"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1158\/1078-0432.CCR-04-0819","article-title":"NY-ESO-1 expression and immunogenicity in esophageal cancer","volume":"10","author":"Fujita S","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.canlet.2004.07.028","article-title":"Expression of cancer\/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters","volume":"219","author":"Peng JR","year":"2005","journal-title":"Cancer Lett"},{"key":"ref60","first-page":"11","article-title":"Cancer\/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer","volume":"4","author":"Wang Y","year":"2004","journal-title":"Cancer Immun"},{"key":"ref61","first-page":"10","article-title":"NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer","volume":"3","author":"Nakada T","year":"2003","journal-title":"Cancer Immun"},{"key":"ref62","first-page":"6076","article-title":"NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer","volume":"63","author":"Odunsi K","year":"2003","journal-title":"Cancer Res"},{"key":"ref63","first-page":"4671","article-title":"Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade","volume":"61","author":"Kurashige T","year":"2001","journal-title":"Cancer Res"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ijc.1451","article-title":"Monophasic and biphasic synovial sarcomas abundantly express cancer\/testis antigen NY-ESO-1 but not MAGE-A1 or CT7","volume":"94","author":"Jungbluth AA","year":"2001","journal-title":"Int J Cancer"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/modpathol.2012.133","article-title":"The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas","volume":"26","author":"Hemminger JA","year":"2013","journal-title":"Mod Pathol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1054\/bjoc.2001.1974","article-title":"Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas","volume":"85","author":"Mashino K","year":"2001","journal-title":"Br J Cancer"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/ijc.20006","article-title":"Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis","volume":"109","author":"Kubuschok B","year":"2004","journal-title":"Int J Cancer"},{"key":"ref68","first-page":"4112","article-title":"Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma","volume":"7","author":"Yin B","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s00262-012-1285-6","article-title":"Cancer\/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients","volume":"61","author":"Inaoka RJ","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/j.1365-2133.2004.06260.x","article-title":"Melanoma or not? Cancer testis antigens may help","volume":"151","author":"L\u00fcftl M","year":"2004","journal-title":"Br J Dermatol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"761378","DOI":"10.1155\/2015\/761378","article-title":"Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma","volume":"2015","author":"Giavina-Bianchi M","year":"2015","journal-title":"J Immunol Res"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1006\/jsre.2001.6148","article-title":"NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma","volume":"98","author":"Goydos JS","year":"2001","journal-title":"J Surg Res"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-05-1544","article-title":"Tumor antigen expression in melanoma varies according to antigen and stage","volume":"12","author":"Barrow C","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref74","first-page":"11","article-title":"Expression of the cancer\/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors","volume":"7","author":"Velazquez EF","year":"2007","journal-title":"Cancer Immun"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ejca.2010.09.042","article-title":"Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate","volume":"47","author":"Svobodov\u00e1 S","year":"2011","journal-title":"Eur J Cancer"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"8396","DOI":"10.1158\/1078-0432.CCR-04-0809","article-title":"Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1","volume":"10","author":"Vaughan HA","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1158\/1078-0432.CCR-03-0813","article-title":"The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome","volume":"10","author":"Oberthuer A","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref78","first-page":"6453","article-title":"Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms","volume":"9","author":"Yakirevich E","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF02893483","article-title":"Expression of cancer-testis antigen CT7 (MAGE-C1) in breast cancer: an immunohistochemical study with emphasis on prognostic utility","volume":"13","author":"Kr\u00fcger S","year":"2007","journal-title":"Pathol Oncol Res"},{"key":"ref80","first-page":"2","article-title":"Prognostic impact of cancer\/testis antigen expression in advanced stage multiple myeloma patients","volume":"8","author":"Andrade VC","year":"2008","journal-title":"Cancer Immun"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1084\/jem.187.8.1349","article-title":"A survey of the humoral immune response of cancer patients to a panel of human tumor antigens","volume":"187","author":"Stockert E","year":"1998","journal-title":"J Exp Med"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood-2004-09-3707","article-title":"NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses","volume":"105","author":"van Rhee F","year":"2005","journal-title":"Blood"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1073\/pnas.97.9.4760","article-title":"Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses","volume":"97","author":"J\u00e4ger E","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/32183","article-title":"Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs","volume":"392","author":"Albert ML","year":"1998","journal-title":"Nature"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"10629","DOI":"10.1073\/pnas.112331099","article-title":"Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations","volume":"99","author":"Nagata Y","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/(SICI)1097-0215(19991022)84:5<506::AID-IJC10>3.0.CO;2-6","article-title":"Humoral immune responses of cancer patients against \"Cancer-Testis\" antigen NY-ESO-1: correlation with clinical events","volume":"84","author":"J\u00e4ger E","year":"1999","journal-title":"Int J Cancer"},{"issue":"33","key":"ref87","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1200\/JCO.2013.51.3002","article-title":"Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study","volume":"31","author":"Thomas NE","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/cncr.21283","article-title":"The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase","volume":"104","author":"Piras F","year":"2005","journal-title":"Cancer"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/modpathol.2012.43","article-title":"Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node","volume":"25","author":"Ma MW","year":"2012","journal-title":"Mod Pathol"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.2011.40.2271","article-title":"Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis","volume":"30","author":"Weide B","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","article-title":"Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1","volume":"358","author":"Hunder NN","year":"2008","journal-title":"N Engl J Med"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins PF","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/modpathol.3800232","article-title":"Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray","volume":"18","author":"Chitale DA","year":"2005","journal-title":"Mod Pathol"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1073\/pnas.1117208109","article-title":"Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients","volume":"109","author":"Odunsi K","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref95","first-page":"9","article-title":"T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein","volume":"7","author":"Uenaka A","year":"2007","journal-title":"Cancer Immun"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/ijc.22583","article-title":"Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients","volume":"120","author":"Kawabata R","year":"2007","journal-title":"Int J Cancer"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1158\/1078-0432.CCR-03-0245","article-title":"NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors","volume":"10","author":"Maraskovsky E","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"9363","DOI":"10.1073\/pnas.0403271101","article-title":"Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant","volume":"101","author":"Chen Q","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"10697","DOI":"10.1073\/pnas.0403572101","article-title":"Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans","volume":"101","author":"Davis ID","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref100","first-page":"1","article-title":"Cancer vacines: an overview","volume":"8","author":"Old LJ","year":"2008","journal-title":"Cancer Immun"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"E590","DOI":"10.1002\/ijc.29118","article-title":"NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus","volume":"136","author":"Chen JL","year":"2015","journal-title":"Int J Cancer"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1476-4598-13-179","article-title":"Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2","volume":"13","author":"Li M","year":"2014","journal-title":"Mol Cancer"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00262-014-1634-8","article-title":"Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1","volume":"64","author":"Dos Santos LI","year":"2015","journal-title":"Cancer Immunol Immunother"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abd\/v92n2\/0365-0596-abd-92-02-0156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:00:44Z","timestamp":1747666844000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0365-05962017000200156&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0365-05962017000200156"],"URL":"https:\/\/doi.org\/10.1590\/abd1806-4841.20176183","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}